The effect of exacerbation history on outcomes in the IMPACT trial

FIGURE 1. Number of combined moderate or severe COPD exacerbations per patient by prior exacerbation subgroup. The exacerbation history subgroups are defined as single moderate (1 moderate/no severe exacerbation in the prior year), frequent moderate (≥2 moderate/no severe exacerbations in the prior year) and severe (≥1 severe/any moderate exacerbation in the prior year). FF: fluticasone furoate; UMEC: umeclidinium; VI: vilanterol.

FIGURE 2. Annual rate of on-treatment a) moderate or severe and b) severe exacerbations (post-hoc analysis) according to exacerbation history in the year prior to screening for each treatment comparison. The exacerbation history subgroups are defined as single moderate (1 moderate/no severe exacerbation in the prior year), frequent moderate (≥2 moderate/no severe exacerbations in the prior year) and severe (≥1 severe/any moderate exacerbation in the prior year). Data are presented as model estimated annual rate (95% CI), unless otherwise stated. FF: fluticasone furoate; RR: rate ratio; UMEC: umeclidinium; VI: vilanterol.

FIGURE 3. Time-to-first combined a) moderate or severe and b) severe COPD exacerbations (post-hoc analysis) by treatment by prior exacerbation subgroup for each treatment comparison. The exacerbation history subgroups are defined as single moderate (1 moderate/no severe exacerbation in the prior year), frequent moderate (≥2 moderate/no severe exacerbations in the prior year) and severe (≥1 severe/any moderate exacerbation in the prior year). Data are presented as patients with events n/N (%), unless otherwise stated. FF: fluticasone furoate; UMEC: umeclidinium; VI: vilanterol.

FIGURE 4. Annual rate of moderate or severe exacerbations, by baseline blood eosinophil count and individual treatment group by prior exacerbation subgroup: a) single moderate, b) frequent moderate and c) severe. The exacerbation history subgroups are defined as single moderate (1 moderate/no severe exacerbation in the prior year), frequent moderate (≥2 moderate/no severe exacerbations in the prior year) and severe (≥1 severe/any moderate exacerbation in the prior year). FF: fluticasone furoate; UMEC: umeclidinium; VI: vilanterol.

FIGURE 5. Between-treatment differences of a, c, e) FF/UMEC/VI versus UMEC/VI and b, d, f) FF/VI versus UMEC/VI in rates of moderate or severe exacerbations, by baseline blood eosinophil count and prior exacerbation subgroup: a, b) single moderate, c, d) frequent moderate, e, f) severe. The exacerbation history subgroups are defined as single moderate (1 moderate/no severe exacerbation in the prior year), frequent moderate (≥2 moderate/no severe exacerbations in the prior year) and severe (≥1 severe/any moderate exacerbation in the prior year). FF: fluticasone furoate; UMEC: umeclidinium; VI: vilanterol.

FIGURE 6. LS mean (95% CI) change in St George's Respiratory Questionnaire (SGRQ) at week 52 by prior exacerbation subgroup. The exacerbation history subgroups are defined as single moderate (1 moderate/no severe exacerbation in the prior year), frequent moderate (≥2 moderate/no severe exacerbations in the prior year) and severe (≥1 severe/any moderate exacerbation in the prior year). Post hoc analysis. Data presented as between-treatment difference (95% CI) in LS mean change from baseline at week 52 in SGRQ total score for FF/UMEC/VI versus UMEC/VI, FF/UMEC/VI versus FF/VI and UMEC/VI versus FF/VI. FF: fluticasone furoate; LS: least squares; UMEC: umeclidinium; VI: vilanterol. *: p<0.05.